Equity · Healthcare
INSM
NASDAQInsmed (INSM)
The line runs 132 USD on 12 August through 108.73 USD on 5 November, on a scale from 80 to 140. Days the market did not trade hold the previous close, flat.
- Market cap
- 23.9B USD
- Revenue, year to Dec 2025
- 606.4M USD
- EPS, diluted, year to Dec 2025
- −6.42 USD
- 52-week range
- 91.87 USD – 212 USD
- Avg volume
- 204.7K
as of Nov 5, 2026
Have Insmed (INSM) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Insmed insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 9 Feb 2026, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 9 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 09 Sep 2026 | Brennan David RDirector | Sell | 25,000 | 3.1M USD |
| 17 Aug 2026 | SHAROKY MELVIN MDDirector | Sell | 5,000 | 638K USD |
| Sold | 2 open-market sales | 30,000 | $3.74M |
2 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 19 Oct 2026 | Hudson PaulDirector | Award | 6,139 | |
| 19 Oct 2026 | Koppikar UtpalDirector | Award | 6,139 |
Which funds hold Insmed (INSM)?
14 of the 45 institutional funds we track reported a Insmed position for the quarter ended 30 Jun 2026 — a combined 3.0B USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Held (±25%) | 8,796,111 | 937.8M USD | +18.5% |
| D. E. Shaw & Co. | Held (±25%) | 5,877,959 | 626.7M USD | +4.5% |
| Citadel Advisors | Held (±25%) | 2,556,973 | 272.6M USD | +17.2% |
| Maverick Capital | New position | 2,150,762 | 229.3M USD | |
| Millennium Management | Added | 2,048,005 | 218.4M USD | +76.9% |
| Duquesne Family Office | Held (±25%) | 1,424,690 | 151.9M USD | +23.4% |
| Balyasny Asset Management | Added | 1,326,430 | 141.4M USD | +498.3% |
| Two Sigma Investments | Added | 1,242,222 | 132.4M USD | +424.1% |
| AQR Capital Management | Held (±25%) | 612,832 | 65.3M USD | −9.3% |
| Point72 Asset Management | New position | 536,997 | 57.3M USD |
Showing the 10 largest of 14 reported positions. The figures above count all of them.
Have members of Congress traded Insmed (INSM)?
The most recent congressional trade disclosed in Insmed is a sale by Josh Gottheimer (house, NJ), dated 10 Jun 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 10 Jun 2026 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 27 days |
| 08 Aug 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Sale | 1K USD–15K USD | 35 days |
| 07 Jul 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Sale | 1K USD–15K USD | 38 days |
| 16 Jun 2025 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 30 days |
| 09 Apr 2025 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 35 days |
| 21 Jun 2024 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 18 days |
| 28 May 2024 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 11 days |
What has been filed or recorded for Insmed (INSM)?
The filings we hold for Insmed, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 18 shares | 2K USD notional · <0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 71 shares | 7K USD notional · <0.001% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 53,525 shares | 5.8M USD notional · 0.024% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.46 USD | |
| 30 Sep 2026 | Financials | Total assets | 2.2B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 726.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.06 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.76 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −6.42 USD | |
| 31 Dec 2025 | Financials | Revenue | 606.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −1.3B USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −6.42 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.75 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −1.70 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.42 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −5.57 USD |
What do people ask about Insmed (INSM)?
What did Insmed shares close at?108.73
Insmed closed at 108.73 USD on 5 Nov 2026, down 1.13% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Insmed’s market cap?23.9B
Insmed is worth 23.9B USD by market value as of 5 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Insmed’s revenue?606.4M
Insmed reported revenue of 606.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Insmed insiders bought or sold shares recently?2 sales
In the 90 days to 10 Nov 2026, Insmed insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 9 Feb 2026, show no open-market purchase. A further 2 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Insmed?14 of 45
14 of the 45 funds we track reported a Insmed position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, D. E. Shaw & Co. and Citadel Advisors. See Funds
Have members of Congress traded Insmed?7 trades
Yes. 7 trades in Insmed appear in the congressional disclosures we hold; the latest is a sale by Josh Gottheimer (House, NJ) dated 10 Jun 2026, filed 7 Jul 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Insmed last report earnings?−0.46
Insmed last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.46 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Gilbert Ray Cisneros, Jr.: United States Department of Defense, Public domain; Josh Gottheimer: Kristie Boyd; U.S. House Office of Photography, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings